DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)

Information source: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cytomegalovirus Retinitis; HIV Infections

Intervention: Sevirumab (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)

Summary

To compare the safety and efficacy of sevirumab (MSL 109; Protovir), human anti-cytomegalovirus (CMV) monoclonal antibody, plus active primary treatment versus placebo plus active primary treatment in AIDS patients with newly diagnosed and relapsed CMV retinitis. Ganciclovir and foscarnet are used for treatment of CMV retinitis, but cause hematologic toxicity and nephrotoxicity, respectively. Despite continued maintenance therapy with these drugs, relapse occurs in 85 percent of patients within 4 months. Studies suggest that MSL 109, a human monoclonal antibody, when given with either ganciclovir or foscarnet, may increase initial response and prolong time to progression in patients with CMV retinitis.

Clinical Details

Official title: A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)

Study design: Primary Purpose: Treatment

Detailed description: Ganciclovir and foscarnet are used for treatment of CMV retinitis, but cause hematologic toxicity and nephrotoxicity, respectively. Despite continued maintenance therapy with these drugs, relapse occurs in 85 percent of patients within 4 months. Studies suggest that MSL 109, a human monoclonal antibody, when given with either ganciclovir or foscarnet, may increase initial response and prolong time to progression in patients with CMV retinitis. Patients are randomized to receive either MSL 109 or placebo every 2 weeks as supplemental therapy to primary CMV treatment.

Eligibility

Minimum age: 13 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria Concurrent Medication: Required:

- Primary CMV treatment.

Patients must have:

- AIDS.

- Active CMV retinitis.

- At least one photographable lesion of one-quarter or more optic disc area in size.

- Undergoing primary treatment for CMV retinitis that is not contraindicated with MSL

109.

- Visual acuity in at least one eye of 3 or more letters on Early Treatment Diabetic

Retinopathy Study ( ETDRS ) chart at 1 meter distance ( Snellen equivalent 5/200 ). Note:

- Exceptions may be made if visual acuity impairment is possibly reversible and there

is at least light perception in that eye. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded:

- Retinal detachment not scheduled for surgical repair.

- Media opacity that precludes visualization of the fundus.

- Active medical problems sufficient to hinder study compliance.

Concurrent Medication: Excluded:

- IVIG.

- CMV immune globulin ( CMVIG ).

- Interferon alpha.

- Interferon gamma.

- Interleukin-2 ( IL-2 ).

Drug or alcohol abuse sufficient to hinder study compliance.

Locations and Contacts

UCSD - Shiley Eye Ctr / SOCA, La Jolla, California 920930946, United States

UCLA - Jules Stein Eye Institute / SOCA, Los Angeles, California 900957003, United States

UCSF - San Francisco Gen Hosp, San Francisco, California 94143, United States

Northwestern Univ / SOCA, Chicago, Illinois 60611, United States

Johns Hopkins Hosp / SOCA, Baltimore, Maryland 212879217, United States

New York Univ Med Ctr / SOCA, New York, New York 10016, United States

Additional Information


Last updated: October 24, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017